Article content
Joe Biden has a problem on his hands, other than the man in the White House who refuses to behave himself or go away.
Biden has too much power. It’s not an issue that was evident in November, when Democrats managed to seize the presidency but lost ground in the House of Representatives and appeared to have failed in a bid to gain control of the Senate. That struck many as an ideal outcome: a new president, a less disruptive agenda, and a divided Congress that would provide a brake on the overexcited members of the Democrats’ most extreme left-wing, with their demands for government jobs for all and a cornucopia of new benefits.
Cleaning up government can start on Capitol Hill
With insider trading so tough to prove, members of Congress should be banned from trading stocks while in office.
By The Editorial BoardUpdated December 28, 2020, 3:00 a.m.
Email to a Friend
US Senator David Perdue of Georgia, now running for reelection in a Georgia runoff, is reportedly the Senateâs most prolific stock trader, and has been investigated by the Justice Department for insider trading.bandres@ajc.com/Bob Andres
The two Republican incumbents locked in heated runoff battles for Georgiaâs two Senate seats â and control of the US Senate â also happen to be among that bodyâs top stock traders.
Bernie Sanders Getting COVID Vaccine Spawns Bernie Gets a Tattoo Memes
On 12/22/20 at 3:38 PM EST
After Senator Bernie Sanders received the COVID vaccine over the weekend, a number of memes have cropped up, joking that the Vermont senator actually got a tattoo instead.
As seen below, the meme places a photo of Sanders with his sleeve rolled up, getting an injection from a doctor, right alongside a picture of a tattoo.
One of the tweets shows an infamously botched tattoo in which someone incorrectly quoted the lyrics to Bon Jovi s 2000 song It s My Life and mistakenly attributed them to Jon Bovi. (The tat in question frequently appears in lists of the worst tattoo mistakes and is a regular meme among tattoo fans.)
âWhen the spotlight found Moderna, they were readyâ: How the Cambridge biotech company became a world renowned success story
By Scott Kirsner Globe Correspondent,Updated December 18, 2020, 7:11 p.m.
Email to a Friend
A year ago, Moderna was not on anyoneâs âMost Likely to Succeedâ list.
As the Cambridge biotech approached its 10th year, the company had yet to get a single product approved for sale by government regulators. Investors werenât particularly hot on its potential, either â after going public in December 2018, Modernaâs stock price hadnât done much over the ensuing 12 months.
There was skepticism about the companyâs approach â using custom-crafted RNA to instruct the bodyâs cells to battle a disease or virus â partly because Moderna hadnât disclosed much data about it. And there were questions about its focus on a dim corner of the biotechology industry that, in the words of biotech entrepreneur and
‘When the spotlight found Moderna, they were ready’: How the Cambridge biotech company became a world renowned success story Scott Kirsner
A year ago, Moderna was not on anyone’s “Most Likely to Succeed” list.
Popular Searches
As the Cambridge biotech approached its 10th year, the company had yet to get a single product approved for sale by government regulators. Investors weren’t particularly hot on its potential, either ― after going public in December 2018, Moderna’s stock price hadn’t done much over the ensuing 12 months.
There was skepticism about the company’s approach using custom-crafted RNA to instruct the body’s cells to battle a disease or virus ― partly because Moderna hadn’t disclosed much data about it. And there were questions about its focus on a dim corner of the biotechology industry that, in the words of biotech entrepreneur and former Biogen research executive Michael Gilman, was “neither sexy nor lucrative”